Galactomannan C

Drug Profile

Galactomannan C

Alternative Names: Carbohydrate polymer; DAVANAT®; GM-CT-01

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pro-Pharmaceuticals
  • Developer Galectin Therapeutics; Icahn School of Medicine at Mount Sinai; Pro-Pharmaceuticals
  • Class Antineoplastics; Mannans; Polymers
  • Mechanism of Action Galectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Colorectal cancer

Highest Development Phases

  • No development reported Malignant melanoma
  • Discontinued Biliary cancer; Breast cancer; Colorectal cancer; Hepatic fibrosis

Most Recent Events

  • 10 Aug 2017 Discontinued - Phase-II for Biliary cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV)
  • 10 Aug 2017 Galectin Therapeutics withdraws a phase II trial prior to enrolment due to financing and re-organisation in Biliary cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT00386516)
  • 30 May 2017 Discontinued - Preclinical for Hepatic fibrosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top